Previous 10 | Next 10 |
Shares of Galapagos (NASDAQ: GLPG) gained over 20% last month, according to data provided by S&P Global Market Intelligence . The Belgian pharmaceutical company reported third-quarter 2019 operating results that reminded investors of its long-term potential. The business generated reven...
An affiliate of Gilead Sciences (NASDAQ: GILD ) has notified Galapagos NV (NASDAQ: GLPG ) that it will exercise the Initial Warrant A, approved by GLPG shareholders on October 22, allowing Gilead to increase its ownership stake to over 25%. More news on: Gilead Sciences, Inc., Galapagos ...
New analyses from filgotinib clinical development program reinforce the investigational medicine’s consistent efficacy and safety profile in the treatment of inflammatory diseases Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announc...
After its massive deal with Gilead Sciences ( GILD ), I re-initiated a big position in Galapagos ( GLPG ) at €145, based on its high cash balance and interesting catalysts for 2020. Galapagos has always been a strong performer, growing at a CAGR of 29% since its IPO in 2015. I expect th...
Gilead Sciences ( GILD ) has been a core holding of mine for quite a while, although much of the returns have to come from dividends instead of actual capital gains. This has been the result of the HCV implosion, a bit ironic as the company has done so much good for that patient group. In ...
Galapagos NV (GLPG) Q3 2019 Results Conference Call October 25, 2019 08:00 AM ET Company Participants Elizabeth Goodwin - VP, IR Onno van de Stolpe - CEO Bart Filius - COO and CFO Walid Abi-Saab - CMO Piet Wigerinck - Chief Scientific Officer Conference Call Participants ...
Image source: The Motley Fool. Galapagos NV (NASDAQ: GLPG) Q3 2019 Earnings Call Oct 25, 2019 , 8:00 a.m. ET Operator Continue reading
Gilead Sciences (NASDAQ: GILD) reported third-quarter results on Oct. 24 that really won't do much for the stock. Revenue was flat year over year, as gains made in the HIV piece of the business were undermined by declines in hepatitis C drug sales. Gilead cited heavy competition for ...
For years, Gilead Sciences ( GILD ) has been plagued by declining sales form their crucial HCV drug franchise causing a painful few years for shareholders. The stock topped $120 back in 2014 and the company finally appears poised for a sustainable turnaround, albeit a minor one. Image Sou...
Galapagos (NASDAQ: GLPG ): 9M GAAP EPS of €4.59. More news on: Galapagos NV, Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...